Topics

Merck to focus on Keytruda, separating out biosimilar business

08:39 EST 12 Feb 2020 | BioPharma-Reporter

The newly separate business will include womenâs health, legacy brands, and its biosimilar business, as the main part of the business retains oncology, vaccines, hospital and animal health.

Original Article: Merck to focus on Keytruda, separating out biosimilar business

NEXT ARTICLE

More From BioPortfolio on "Merck to focus on Keytruda, separating out biosimilar business"

Quick Search

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...